Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DURBAC: Durvalumab and BVAC-C in Recurrent Cervical Cancer
NCT04800978Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jun 2021
- Primary completion
- Aug 2024
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
01
Overview
A Phase 2 trial of BVAC-C in Cervical Cancer (CC), sponsored by Samsung Medical Center. Status: unknown.
02
Drugs
BVAC-C
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04800978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04800978.